CROI 2024 Abstract eBook

Abstract eBook

Oral Abstracts

women suggest that drug levels are higher in the rectum than the vagina and lower in the presence of estrogen, and yet despite these differences across sex and gender, daily oral Tenofovir Disoproxil Fumarate-Emtricitabine is highly effective at preventing incident HIV in all populations. Are these differences in drug concentrations a valid justification limiting event-driven PrEP use to cisgender men who have sex with men? In many settings, cisgender women who are not interested in or have barriers to daily dosing, even in settings of infrequent sexual exposures, have been dissuaded from using oral PrEP due to concerns about the need for perfect adherence for vaginal protection. Seven doses of oral PrEP a week offers excellent protection against HIV and recent retrospective data demonstrated that four single strength doses a week had similarly high protection among cisgender women suggesting that dosing frequency needs may not differ by sex assigned at birth.

Oral Abstracts

15

CROI 2024